| Christopher Jordan, MD | |
|
611 E Douglas Rd Ste 137, Mishawaka, IN 46545-1464 | |
| (574) 335-6214 | |
| (574) 335-6215 |
| Full Name | Christopher Jordan |
|---|---|
| Gender | Male |
| Speciality | Sports Medicine |
| Experience | 12 Years |
| Location | 611 E Douglas Rd Ste 137, Mishawaka, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689938664 | NPI | - | NPPES |
| 201110900 | Medicaid | IN | |
| 01072993A | Other | IN | IN STATE MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QS0010X | Family Medicine - Sports Medicine | 01072993A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Joseph Regional Medical Center | Mishawaka, IN | Hospital |
| Saint Joseph Regional Medical Center - Plymouth | Plymouth, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Joseph Regional Medical Center- Plymouth Campus Inc | 9537071337 | 19 |
| Saint Joseph Regional Medical Center-south Bend Campus Inc | 3476451790 | 77 |
News Archive
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease.
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.
Claimsnet.com inc., a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2012, which ended June 30, 2012.
Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).
› Verified 4 days ago
| Entity Name | Saint Joseph Regional Medical Center- Plymouth Campus Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538585187 PECOS PAC ID: 9537071337 Enrollment ID: O20031223000588 |
News Archive
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease.
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.
Claimsnet.com inc., a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2012, which ended June 30, 2012.
Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).
› Verified 4 days ago
| Entity Name | Saint Joseph Regional Medical Center-south Bend Campus Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841245594 PECOS PAC ID: 3476451790 Enrollment ID: O20031223000724 |
News Archive
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease.
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.
Claimsnet.com inc., a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2012, which ended June 30, 2012.
Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).
› Verified 4 days ago
| Entity Name | Saint Joseph Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225082878 PECOS PAC ID: 8325950843 Enrollment ID: O20040708000757 |
News Archive
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease.
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.
Claimsnet.com inc., a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2012, which ended June 30, 2012.
Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Jordan, MD 707 Cedar St Ste 405, South Bend, IN 46617-2059 Ph: () - | Christopher Jordan, MD 611 E Douglas Rd Ste 137, Mishawaka, IN 46545-1464 Ph: (574) 335-6214 |
News Archive
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease.
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.
Claimsnet.com inc., a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2012, which ended June 30, 2012.
Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).
› Verified 4 days ago
Theodore R Neumann, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 611 E Douglas Rd Ste 406, Mishawaka, IN 46545 Phone: 574-335-6580 | |
Dr. Josephine Schimizzi, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1505 South Spring Street, Mishawaka, IN 46544 Phone: 574-255-0726 | |
Dale Dennis Deardorff, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 420 W 4th St, Suite 180, Mishawaka, IN 46544 Phone: 574-247-3456 Fax: 574-247-3455 | |
James Mccarrey, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4630 Vistula Rd, Mishawaka, IN 46544 Phone: 574-647-1900 | |
Dr. Jack S. Bartoszek, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 615 Fulmer Rd, Mishawaka, IN 46544 Phone: 574-252-3085 Fax: 574-252-5906 | |
Dr. Lawrence R Curry, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 524 E Mckinley Ave, Mishawaka, IN 46545 Phone: 574-256-2556 Fax: 574-258-4278 | |
Jennifer Anne Pennington, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4630 Vistula Rd, Mishawaka, IN 46544 Phone: 574-647-1900 Fax: 574-254-7222 |